BioCentury
ARTICLE | Company News

Corixa licenses AnergiX.MG to Beaufour

January 15, 2002 8:00 AM UTC

CRXA granted Beaufour Ipsen (Paris, France) exclusive worldwide development and marketing rights to its AnergiX.MG T cell inactivation technology to treat myasthenia gravis, an autoimmune neuromuscula...